Please assess the completion status of the following clinical trial:

Trial Title: Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically and/or cytologically confirmed primary diagnosis of NSCLC, Stage IV, Stage IIIB or IIIC not amenable to definitive curative intent therapy, or recurrent disease after prior diagnosis of Stage I-III disease. Cohort C locally advanced or metastatic solid tumor.~* Progression of disease on or after a platinum-based chemotherapy regimen (Cohorts A and B) or after standard of care (Cohort C)~* EGFR exon 20 insertion mutation (Cohort A) or HER2 activating mutation (Cohort B) or NRG1 or ERBB family gene fusions (Cohort C)~* Measurable disease according to RECIST v.1.1~* ECOG performance status of 0 or 1~* Serum creatinine ≤ 1.5 x ULN (or calculated creatinine clearance ≥ 60 mL/min using Cockcroft Gault equation)~* Total bilirubin: ≤ 1.5 x ULN or ≤ 3 x ULN in the presence of liver metastases~* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN, in the presence of liver metastases~* Absolute neutrophil count (ANC) ≥ 1,500 cells/μL~* Hemoglobin ≥ 9 g/dL or 5.6 mmol/L~* Platelet count ≥ 100,000/μL~* No evidence of second or third degree atrioventricular block~* No clinically significant arrhythmia (i.e.; pauses of \> 4 seconds, VT of any duration, SVT \> 4 beats/minute)~* QRS interval ≤ 110 ms~* QTcF interval of \< 450 ms~* PR interval ≤ 200 ms~* Adequate pretreatment tumor sample (125 µm of FFPE block or at least 8 prepared slides)~Key Exclusion Criteria:~* Another known activating oncogene driver mutation~* (Cohorts A and B Only) Previously received anti EGFR or anti HER2 tyrosine kinase inhibitors~* (Cohorts A and B Only) Previously received anti EGFR or anti HER2 monoclonal antibodies or EGFR or HER2 antibody drug conjugates~* Investigational therapy administered within the 28 days or 5 half lives~* Chemotherapy or radiation within 14 days prior to Cycle 1 Day 1~* Immunotherapy within 21 days~* Clinically active or symptomatic interstitial lung disease (ILD) or interstitial pneumonitis, or a history of clinically significant ILD or radiation pneumonitis~* Untreated and/or symptomatic CNS malignancies (primary or metastatic);~* Receiving medication that prolongs QT interval, with a risk of causing Torsade de Pointes (TdP)~* Personal or familial history of Long QT Syndrome~* NYHA class III or IV or LVEF \< 55%~* Myocardial infarction, severe or unstable angina within 6 months~* History of TdP, ventricular arrhythmia~* Significant thrombotic or embolic events within 3 months~* Uncontrolled or severe cardiovascular disease~* Concurrent malignancy expected to require treatment within 2 years or interfere with study outcomes~* History of severe allergic reactions or hypersensitivity to compounds of similar chemical or biologic composition as tarloxotinib~* Known HIV infection or active Hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): tarloxotinib bromide

Based on this trial design, predict the completion outcome and termination type (if applicable).